Scilex today announced that the U.S. Patent and Trademark Office has allowed numerous claims from U.S. patent application no. 17/562,229 and will issue a new patent containing those claims related to the treatment of acute pain (the "Patent"), to Scilex in late 2024, further strengthening the Company's intellectual property position and coverage for its acute migraine treatment drug product, ELYXYB®, a liquid, micro-encapsulation formulation of celecoxib. ELYXYBTM is a first-line treatment and the only FDA- ...